# Jennifer R. Brown

Source: https://onco.cc/people/jennifer-brown/  
OnCo record `jennifer-brown` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led ALPINE, the first head-to-head trial in which a next-generation BTK inhibitor (zanubrutinib) beat ibrutinib.

## Summary

Jennifer Brown was principal investigator of ALPINE, which showed zanubrutinib improves progression-free survival and causes fewer cardiac events than ibrutinib in relapsed CLL, and led early work on idelalisib and the genetics of familial CLL. She directs the CLL centre at Dana-Farber and leads trials of non-covalent BTK inhibitors and BTK degraders for resistant disease.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: cll; btk; trialist
- Role: Director, CLL Center, Dana-Farber Cancer Institute; Worthington and Margaret Collette Professor of Medicine, Harvard Medical School
- Specialisms: Chronic lymphocytic leukaemia; BTK inhibitors; CLL genetics; Novel agents

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Brown%20JR%5BAuthor%5D%20chronic%20lymphocytic%20leukemia%20zanubrutinib

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/)
- technologies: [PROTACs & molecular glues (targeted protein degradation)](https://onco.cc/technologies/protac-degrader/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- institutions: [Dana-Farber Brigham Cancer Center](https://onco.cc/institutions/dana-farber/)
- trials: [ALPINE](https://onco.cc/trials/alpine/), [BRUIN CLL-321](https://onco.cc/trials/bruin-cll-321/)

---
JSON: https://onco.cc/api/v1/entities/jennifer-brown.json